Business
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company’s NaV1.1 program in Dravet syndrome VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 at the Georgia World Congress Center in Atlanta, Georgia. Seven posters will be presented, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), and data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. Xenon’s poster presentations also include findings on the impact of depression on epilepsy patients, as well as new pre-clinical data from the Company’s early-stage NaV1.1 program in Dravet syndrome. Long-Term Data for Azetukalner in Epilepsy Poster Presentation #1.377: Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical PracticeAuthor Session: Saturday, December 6 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 1 Poster Presentation #3.356: Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults with Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label ExtensionAuthor Session: Monday, December 8 from 12:00 – 1:45 pm ET in Poster Hall B3, Poster Session 3 Epilepsy Real World Studies Poster Presentation #1.364: Depression Symptom Experience Among Patients with Epilepsy Reporting a Diagnosis of Focal Seizures (FS): A Patient-Reported Outcomes StudyAuthor Session: Saturday, December 6 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 1 Poster Presentation #1.365: Impact of Depression on Outcomes and Treatment Patt...